OTHER INFORMATION
+Added: On August 4, 2020, the Company entered into an Employee Severance Agreement (the “Severance Agreement”) with Don Kalkofen, the Company’s Chief Financial Officer.
+Added: The Severance Agreement provides that if the Company terminates Mr.
+Added: Kalkofen’s employment without "cause"
+Added: Kalkofen terminates employment for "good reason"
+Added: (each as defined in the Severance Agreement), Mr.
+Added: Kalkofen will receive:
+Added: (a) salary continuation for nine months (12 months in the case of a “change in control termination” (as defined in the Severance Agreement));
+Added: (b) COBRA continuation for the salary continuation period (or an equivalent cash payment if required by law);
+Added: (c) in the case of a change in control termination only , payment of an amount equal to one twelfth of Mr.
+Added: Kalkofen’s then current target bonus per month for the number of months of the severance period;
+Added: and (d) in the case of a change in control termination only, acceleration of the vesting (and exercisability, as relevant) of equity awards held by Mr.
+Added: Kalkofen immediately prior to termination.
+Added: Payments and benefits under the Severance Agreement are subject to the execution of an effective release.
EXHIBIT INDEX
3 unchanged sentences
Amended and Restated Bylaws
−Removed: Protagonist Therapeutics, Inc.
−Removed: Amended and Restated 2018 Inducement Plan
+Added: Severance Agreement, dated August 4, 2020, by and between Protagonist Therapeutics, Inc.
+Added: and Don Kalkofen
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
1 unchanged sentence
Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
−Removed: §1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: XBRL Instance Document
+Added: §1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
XBRL Taxonomy Extension Schema Document
3 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
+Added: Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
+ Filed herewith
4 unchanged sentences
PROTAGONIST THERAPEUTICS, INC.
+Added: August 6, 2020
/s/ Dinesh V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 6, 2020
/s/ Don Kalkofen
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.